Taro gets FDA approval for anti-cancer cream

The equivalent branded treatment had sales of $70 million in the US in 2009.

Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) today reported that it received approval from the US Food and Drug Administration (FDA) for fluorouracil cream. Fluorouracil is bioequivalent to Efudex Topical Cream 5% manufactured by Valeant Pharmaceuticals International.

Taro’s fluorouracil cream is a prescription dermatological pharmaceutical product used for topical treatment of multiple actinic, or solar, keratoses and superficial basal cell carcinomas.

Solar keratoses are lesions due to overexposure to the sun. Basal cell carcinomas are among the most common forms of skin cancer.

. According to industry sources, Efudex had annual US sales in 2009 of $70 million.

Taro's share closed at $12.70 yesterday.

Published by Globes [online], Israel business news - www.globes-online.com - on March 9, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018